RecruitingNCT04616131
Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy
Sponsor
Northwestern University
Enrollment
500 participants
Start Date
Oct 1, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Biopsy or cytology proven adenocarcinoma of the pancreas
- No clinical evidence of metastatic disease on imaging
- Age 18 or older
- Receiving chemotherapy for non-metastatic pancreatic cancer
Exclusion Criteria1
- Biopsy proven metastatic disease
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04616131
Related Trials
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
NCT019152251 location
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
NCT064792391 location
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT0605169512 locations
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
NCT054031773 locations
Autologous CAR-T Cells Targeting B7-H3 in PDAC
NCT061581391 location